Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content
Archive

Table 5. Guidelines for postexposure immunoprophylaxis of unvaccinated persons who have an identifiable exposure to blood or body fluids that contain blood

 
This web page is archived for historical purposes and is no longer being updated. Newer content is available at www.cdc.gov/std/treatment
 

Sexually Transmitted Diseases Treatment Guidelines, 2010

CauseAction
Exposure to an HBsAg*-positive sourcePercutaneous (e.g., bite or needlestick) or mucosal exposure to HBsAg-positive blood or body fluids that contain bloodAdminister hepatitis B vaccine & HBIG†
Sexual or needle-sharing contact of an HBsAg-positive personAdminister hepatitis B vaccine & HBIG†
Victim of sexual assault/abuse by a perpetrator who is HBsAg positiveAdminister hepatitis B vaccine & HBIG†
Exposure to a source with unknown HBsAg statusVictim of sexual assault/abuse by a perpetrator with unknown HBsAg statusAdminister hepatitis B vaccine†
Percutaneous (e.g., bite or needlestick) or mucosal exposure to blood or body fluids that contain blood from a source with unknown HBsAg statusAdminister hepatitis B vaccine†

* Hepatitis B surface antigen.
† Immunoprophylaxis should be administered as soon as possible, preferably ≤24 hours. Studies are limited on the maximum interval after exposure during which postexposure prophylaxis is effective, but the interval is unlikely to exceed 7 days for percutaneous exposures and 14 days for sexual exposures. The complete, 3-dose hepatitis B vaccine series should be administered.

Top